Immunocore Holdings (IMCR) Total Non-Current Liabilities (2019 - 2025)

Immunocore Holdings (IMCR) has reported Total Non-Current Liabilities for 7 consecutive years, with $609.3 million the latest figure, recorded in Q3 2025.

• Quarterly Total Non-Current Liabilities fell 13.42% year-over-year to $609.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $609.3 million (down 13.42% YoY) and the FY2024 annual result came in at $648.8 million, up 185.58% from the prior year.
• Total Non-Current Liabilities was little changed at $609.3 million in Q3 2025 per IMCR's latest filing, from $609.9 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for IMCR reached as high as $703.8 million in Q3 2024 and fell as low as $85.6 million in Q3 2022.
• A 5-year average of $419.5 million and a median of $598.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities dropped 18.84% — and 2024, when it jumped 647.38%.
• Year by year, Total Non-Current Liabilities stood at $93.1 million in 2021, then decreased by 7.16% to $86.4 million in 2022, then soared by 162.9% to $227.2 million in 2023, then surged by 185.58% to $648.8 million in 2024, then retreated by 6.08% to $609.3 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $609.3 million, $609.9 million, and $587.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.